Skip to main content
Equibles
GLSI logo

GLSI · Greenwich LifeSciences, Inc.

Track GLSI — free Ask ALVIS about GLSI
$14.02 +1.22 (+9.53%) At close · Jul 30
Going-concern doubt — flagged Jun 4, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has incurred net losses since its inception and has negative operating cash flows. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements are issued.”
View the 10-Q filed Jun 4, 2026
Market Cap
$205.79M
Shares
14.68M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.02 Open$12.97 Day$12.97–14.35 52W$7.78–34.10 Avg vol 30d174K Short int1.5M · 10.0% float · 12.1d Short vol52% DataSep 2020–Jul 2026 Filing10-Q · Jun 4

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Jun 4, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 17.1 · elevated Equity put/call 0.61
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −31%
below
Price vs 50-day avg −34%
below
RSI (14) 36
neutral
MACD trend Negative
52-week position 24%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −41%
trailing
6-month return −44%
trailing
YTD return −33%
this year
Relative strength −54%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $21 › 200d $20 — 50d above 200d
Institutional flow Accumulating
11 of 63 funds reported for Jun 30 · net +4.1K sh shares · +1 new
Insider flow Accumulating
Net +$97.0K over 90 days · 0% sells
Short interest Rising
10.00% of float · ▲ +0.7% MoM · 12.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
63 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Fair
EPS growth −7%
Y/Y
Balance sheet $6.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 98%
annualized · 1-yr
Max drawdown −62%
past year
ATR 13.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−31% Bearish
Price vs 50-day avg
−34% Bearish
RSI (14)
36 Neutral
MACD trend
Negative Bearish
52-week position
24% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $21 › 200d $20 — 50d above 200d
Institutional flow Accumulating
11 of 63 funds reported for Jun 30 · net +4.1K sh shares · +1 new
Insider flow Accumulating
Net +$97.0K over 90 days · 0% sells
Short interest Rising
10.00% of float · ▲ +0.7% MoM · 12.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
63 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $8 Now $14 · 24% 52-wk high $34
vs 200-day avg -31% vs 50-day avg -34%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GLSI
Greenwich LifeSciences, Inc.
this stock
$205.79M -33.3% — — 10.0%
ONC
BeOne Medicines Ltd.
 $465.49B +6.0% +22179.2% 947.3 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $122.26B +6.3% +46.2% 28.6 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
 $76.02B -4.2% +20.8% 18.3 3.4%
ARGX
Argenx SE
 $54.59B +3.8% — — 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
63
% held
11.3%
Reported
11 of 63
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
81
View
Short & Settlement
Short Interest Rising
Shares short
1.5M
Days to cover
12.1d
Change
+9.7K sh
View
Short Volume
Short vol %
52%
As of
Jul 30, 2026
Short Total
View
Fails to Deliver
FTD shares
1.2K
Value
$21.6K
As of
Jul 14, 2026
View
Off-Exchange
Off-exchange %
56.7%
Week of
May 4, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$97.0K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-19.4M
EPS diluted
$-1.43
View
Buybacks
Authorized
shares 519.8K
Remaining
shares 519.8K
Spent Remaining
View
Filings
SEC Filings
Latest
10-Q
Filed
Jun 4, 2026
This year
2
View
Exempt Offerings
Offering
$2.5M
Filed
Jun 18, 2024
View
Earnings & Events
Earnings Calls
Last call
Dec 3, 2025
View

Performance

5D 20D 120D MTD YTD
GLSI +6.3% -40.8% -44.3% -40.2% -33.3%
SPY +0.5% -0.6% +9.5% -0.7% +8.8%
vs SPY +5.8% -40.3% -53.8% -39.6% -42.0%

Capital returns

Buyback program · as of Dec 31, 2022
Authorized
shares 519,828
Spent (derived)
shares 0
Remaining
shares 519,828
Spent Remaining

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1799788 CUSIP 396879108 13F (30d) 10 filings 10 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)